There's a clear pattern in the moves $HIMS has made lately, and it shows where Andrew Dudum is taking the company. Hims is becoming the platform people use to manage their health throughout their whole lives. First came the GRAIL partnership, which put Galleri cancer screening on the platform at $250 off the $949 list price for Labs members. One blood draw looks for a signal from more than 50 types of cancer. Now Hims has invested in Arboretum, a genetic testing company that launched this week with a $30M Series A, with Hims in the round alongside GV and Amgen. Arboretum's tests look at inherited disease risk. The results show doctors who needs earlier screening, closer monitoring or a particular treatment. Finding the inherited condition behind very high cholesterol, for example, means
View on X ↗